Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852183 | 0.82 | TSHR (0.50) | TSHRALDH1A1HSD17B10TDP1SRC | |
| SCHEMBL4589500 | 0.78 | SRC (0.54) | TSHRALDH1A1TDP1SRCCYP2C19 | |
| SCHEMBL4440349 | 0.78 | TSHR (0.46) | TSHRALDH1A1SRCDPP4F2 | |
| SCHEMBL5200599 | 0.78 | TSHR (0.46) | TSHRALDH1A1HSD17B10TDP1SRC | |
| SCHEMBL5200608 | 0.78 | TSHR (0.46) | TSHRALDH1A1HSD17B10TDP1SRC | |
| SCHEMBL5886893 | 0.77 | CYP2C19 (0.48) | TSHRALDH1A1HSD17B10TDP1SRC | |
| SCHEMBL9449886 | 0.77 | TSHR (0.74) | TSHRALDH1A1HSD17B10TDP1SRC | |
| SCHEMBL1412817 | 0.77 | ALDH1A1 (0.46) | TSHRALDH1A1HSD17B10TDP1SRC | |
| SCHEMBL1500758 | 0.76 | CYP19A1 (0.40) | ALDH1A1HSD17B10TDP1CYP2C19LMNA | |
| SCHEMBL11574577 | 0.76 | CA1 (0.47) | TSHRALDH1A1HSD17B10SRCCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4131619-A | Preparation of 2-chloro-4-toluenesulfonyl chloride | THE DOW CHEMICAL COMPANY (US) | 1978-12-26 | — | — | US | claimed |
| EP-2546239-B1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2546239-B1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2014165196-A1 | DETECTION OF GAS-PHASE ANALYTES USING LIQUID CRYSTALS | PLATYPUS TECHNOLOGIES, LLC (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| CN-101184729-A | Cytosolic phospholipase A2Inhibitors | WYETH CORP (US) | 2008-05-21 | — | — | CN | disclosed |
| EP-1919464-A1 | OXADIAZOLE COMPOUNDS AS UROKINASE INHIBITORS | Wilex AG (DE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007025718-A1 | OXADIAZOLE COMPOUNDS AS UROKINASE INHIBITORS | WILEX AG (DE) | 2007-03-08 | — | — | WO | disclosed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-4141808-A | Manganese carbonyl-sulfonyl chloride photoinitiators for radiation polymerizable unsaturated compounds | EASTMAN KODAK COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
| US-4131619-A | Preparation of 2-chloro-4-toluenesulfonyl chloride | THE DOW CHEMICAL COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4131619-A | Preparation of 2-chloro-4-toluenesulfonyl chloride | THE DOW CHEMICAL COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128783-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | TSHR 375/4885ALDH1A1 2298/4885HSD17B10 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.